Tofogliflozin most effective with high baseline insulin

Tofogliflozin most effective with high baseline insulin

(HealthDay)—The sodium glucose co-transporter 2 inhibitor tofogliflozin is effective for reducing fasting plasma glucose and body weight, particularly in patients with a high insulin level at baseline, according to a study published online Oct. 15 in the Journal of Diabetes Investigation.

Kazuyuki Tobe, M.D., Ph.D., from the University of Toyama in Japan, and colleagues conducted a sub-analysis of a multicenter, open-label, 52-week, randomized controlled trial of
tofogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus. Patients were categorized into tertiles by baseline level: low (L) insulin (≤5.6 µU/mL), medium (M) insulin (5.6 to 10µU/mL), and high (H) insulin (>10µU/mL).

The researchers found that HbA1c, fasting levels, and were significantly reduced from the baseline in all three groups. The changes in levels of plasma glucose AUC0-2 hours, C-peptide index AUC0-2 hours during the meal tolerance tests, and the insulin secretion index were the largest in the H group. The three groups were similar in terms of incidence of drug-related adverse events.

"Although tofogliflozin was effective regardless of baseline insulin level, it showed the highest efficacy in the H group," conclude the authors.

The authors disclosed financial ties to the pharmaceutical industry. Chugai Pharmaceutical Co. funded the original phase 3 trial.


Explore further

Biosimilar insulin lispro shown not inferior to Humalog in efficacy or safety

More information: Abstract/Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Tofogliflozin most effective with high baseline insulin (2017, October 24) retrieved 29 May 2020 from https://medicalxpress.com/news/2017-10-tofogliflozin-effective-high-baseline-insulin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments